Bringing precision medicine to the patients who need it most.
Acurion’s OncoGaze™ enables early detection of HRD* across ovarian, breast, and pancreatic cancer.
*and that’s just the beginning!
OncoGaze is initially focused on identifying HRD status, a clinically actionable biomarker in three of the most aggressive solid tumors: ovarian, breast, and pancreatic cancer.
With OncoGaze, oncologists will be able to prescribe optimal treatments right at the time of biopsy.
Why this matters:
Next Generation Sequencing (NGS) is the current standard of care, but it is not perfect:
4-5
weeks
NGS can take too long. By the time NGS results arrive, it may be too late for patients to be eligible for the most optimal treatments.
15%
QNS
Insufficient Tissue Quantities (QNS) causes delays. 15% of NGS tests fail this way, leading to treatment delays.
.5x
detection rate
NGS testing misses many true HRD patients, limiting opportunities for targeted intervention.
Look, we love Next Generation Sequencing.
NGS has, and will continue to provide a number of insights in oncology and many other fields. NGS taught us how to look for genomic activity in cells, what causes phenotypic changes, and why they are important. NGS has been a blueprint for us. And that’s exactly what NGS is looking at, our blueprints, our DNA.
But the systems in place for looking at our blueprints are flawed and in reality what we really need to be looking at for conditions like HRD are the cells themselves. That’s exactly what OncoGaze does. And by doing so we are more accurate, more accessible, more affordable, and much faster than NGS.
Simply put, many cancer patients can’t wait several weeks for an NGS test that may or may not actually detect HRD or not. There is a better way, and that way is OncoGaze.
Let's bring precision oncology forward – together.
Explore how Acurion is driving immediate precision for optimal care. Contact us for a demo of OncoGaze.